Clinical Scorecard: Enterovirus diversity may limit treatment advances
At a Glance
| Category | Detail |
|---|---|
| Condition | Enterovirus infections in children |
| Key Mechanisms | Viral entry mechanisms, rapid evolution, antigenic variation |
| Target Population | Pediatric patients, particularly those with severe disease |
| Care Setting | Pediatric clinical settings |
Key Highlights
- Molecular testing is central to EV diagnosis with over 95% sensitivity.
- Treatment remains primarily supportive; no antiviral drug is approved for routine use.
- Investigational antiviral candidates have stalled in development.
- The inactivated EV-A71 vaccine shows over 90% efficacy against severe HFMD.
- Challenges include genetic diversity and lack of cross-protection among EVs.
Guideline-Based Recommendations
Diagnosis
- Use molecular testing alongside clinical manifestations and epidemiologic information.
Management
- Supportive care including fluid management, antipyresis, and seizure control.
Monitoring & Follow-up
- Monitor for severe disease and complications, particularly in immunocompromised patients.
Risks
- Severe disease and death can occur, especially in vulnerable populations.
Patient & Prescribing Data
Pediatric patients with enterovirus infections
Supportive care is the mainstay; investigational treatments are largely unproven.
Clinical Best Practices
- Prioritize broad-spectrum antiviral agents with high resistance barriers.
- Consider pediatric safety in treatment approaches.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
